Comparable to clinical approval by the European Medicines Agency or the U.S. Food and Drug Administration, reimbursement approval is very restricted.
Philadelphia and Washington could become linked the way Manhattan and Brooklyn are today, if the travel costs are comparable (recall, before approval of the New York subway, that the boroughs were separate cities).
Though not directly comparable, the perceived approval rating outshines those of Western leaders.
The envisaged systems of sustainability standards that might also contain exclusion criteria is, to a certain extent, comparable with the approval system of GMOs, and thus the features of their SEAs might also be applicable for biosafety policy and GMO project analysis.
This directive is a forward step in terms of the internal market, because its consequence will be that many national regulations current in Europe will be harmonised, the objective being to have equal and comparable criteria for approval, and especially to ensure the removal of distortions to competition in this area too.
The time to protocol approval was comparable for non-industry and industry-sponsored trials, but was significantly different between RECs.
If a product meets the definition of a dietary supplement, no premarket approval system comparable to that of the NDA or biologics license application ("BLA") rubrics applies.
Since campaign reform has already passed the Senate in the form of a bill sponsored by Senators John McCain and Russell Feingold, approval of a comparable measure in the House, known as Shays-Meehan, can speed the bill into law.
According to Gallup, Mr. Obama's current mid-40s approval ratings are comparable to or slightly higher than Mr. Reagan's at a similar point in 1982 (as well as Mr. Clinton's in 1994).
However, as demonstrated by the Huntington/FirstMerit and Key/First Niagara transactions this year and others, such as BB&T's acquisitions of Susquehanna and National Penn last year, large complex transactions can still obtain regulatory approval in timeframes comparable to pre-crisis transactions.
But in April, the Biotechnology Industry Organization, a trade group based in Washington, petitioned the F.D.A. to withdraw draft rules that would have allowed comparable biologics to be eligible for approval.
